AI developer Spectral AI has achieved 100% pediatric patient enrollment at burn centers for its 2024 study designed to validate the AI-driven algorithm used by the company's DeepView System for its burn indication.
The study is scheduled to be completed in the fourth quarter of 2024 and is the final clinical trial before the company seeks approval from the U.S. Food and Drug Administration (FDA) for the DeepView System for burn indication in 2025.
Spectral AI’s DeepView System uses proprietary multispectral imaging, trained and tested against a proprietary database of more than 340 billion clinically validated data points to distinguish between healthy and damaged tissue. The system can be used immediately upon a child’s arrival at the emergency department or burn center, providing noninvasive, cart-based wound assessments in support of timely clinical decision-making for burn injuries.
